By Fineline Cube 
Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500 million Series A+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State‑owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI‑driven islet differentiation platform, and expand digital manufacturing capacity.
Financing Details
| Item | Detail |
|---|---|
| Company | Reprogenix Bioscience Inc. |
| Amount | RMB 500 million (Series A+) |
| Lead Investor | CRS Fund |
| Co‑Investors | Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State‑owned Capital Investment, Beijing Gage, Beicheng Fund |
| Use of Proceeds | Clinical advancement, AI islet platform, automated production, global expansion |
| Valuation | Not disclosed; post‑money estimated at RMB 2.0‑2.5 billion |
Company Profile
- Founded: 2014
- Focus: Cell therapy for Type 1 and Type 2 diabetes
- Pipeline: Two core assets in clinical/late preclinical stage
- Technology: AI virtual cell platform for islet differentiation; digital, intelligent, automated GMP manufacturing
- Strategic Edge: First domestic company with Type 1 diabetes cell therapy in Phase I
Pipeline Overview
| Product | Indication | Stage | Status |
|---|---|---|---|
| RGB‑5088 | Type 1 diabetes | Phase I | Approved for clinical trial; leading domestically |
| RGB‑T2D* | Type 2 diabetes | IND‑enabling | Clinical trial application accepted by NMPA; entry imminent |
*Internal code; branded name pending
Technology Platform
- AI Virtual Cells: Accelerates islet differentiation protocol optimization, reducing development time by 30‑40% vs. traditional methods
- Automated Manufacturing: Closed‑system bioreactors and AI‑driven quality control enable scale‑up to 10,000+ doses/year per facility
- Cost Position: Targeting 60‑70% cost reduction vs. manual production, critical for diabetes cell therapy commercial viability
Market Impact & Outlook
| Metric | Value |
|---|---|
| China Diabetes Patients | 141 million (Type 2: 90%; Type 1: ~1 million) |
| Cell Therapy Penetration Target | Type 1: 5% (50,000 patients); Type 2: 0.1% (140,000 patients) |
| Pricing | Type 1: ¥150,000‑200,000/dose; Type 2: ¥80,000‑120,000/dose |
| Peak Market Potential | ¥50‑70 billion (US$7‑10 billion) by 2035 |
| Manufacturing Capacity | First GMP facility (Hangzhou) operational 2026; second facility (Sichuan) planned 2027 |
| Global Strategy | Partnership discussions underway for US/EU Phase I trials; leveraging AI platform for IND‑ready packages |
- Competitive Moat: Only domestic player in Phase I for Type 1; multinational rivals (e.g., Vertex via ViaCyte, Sana Biotechnology) remain pre‑clinical or early clinical in China.
- Reimbursement Path: Type 1 cell therapy likely to receive breakthrough designation and priority NRDL review; Type 2 may require real‑world evidence for broader coverage.
- Funding Runway: Series A+ extends runway to Q4 2027, enabling two Phase I readouts and Type 2 IND filing.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Reprogenix’s clinical development, manufacturing scale‑up, and market penetration. Actual results may differ materially due to risks including clinical trial outcomes, regulatory review timelines, and competitive dynamics in cell therapy.-Fineline Info & Tech